News Desk — April 9, 2018 at 6:36 am — Updated: April 9, 2018 at 6:36 am

Novartis shells out $8.7 billion to buy AveXis


ZURICH (Reuters) – Novartis said on Monday it plans to buy AveXis for $218 per share in a cash deal totalling $8.7 billion (£6.1 billion) as the Swiss drugmaker adds a company whose top drug hopeful, for spinal muscular atrophy, has U.S. breakthrough therapy designation.

Leave A Comment Using Facebook (Website Comment Form Below)

Use the form below to post a comment via facebook

Leave a Reply

69 queries in 1.046 seconds.